Pulmonary & Respiratory Medicine

Lung Cancer Biomarkers

The discovery and application of biomarkers have significantly advanced the early detection and treatment of lung cancer. This session will focus on the role of molecular and genetic biomarkers in improving diagnostic accuracy and guiding personalized treatment strategies. Biomarker research has become a cornerstone in modern oncology, helping clinicians identify specific molecular characteristics of lung tumors. Experts will discuss emerging biomarkers that assist in predicting disease progression, treatment response, and patient prognosis. Advances in molecular diagnostics and genomic profiling are enabling healthcare professionals to identify specific mutations and alterations associated with lung cancer development. These insights are essential for selecting targeted therapies and optimizing patient outcomes. The session will also explore non-invasive diagnostic techniques, such as liquid biopsy and circulating tumor DNA analysis, which allow clinicians to monitor disease progression and treatment effectiveness. These technologies provide new opportunities for early detection and real-time monitoring of lung cancer. Participants will gain a deeper understanding of how biomarker-driven approaches are transforming lung cancer management. Continued research in this field is expected to lead to more precise diagnostic tools, improved treatment strategies, and enhanced survival rates for patients with lung cancer.